PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
PARIS and NES-ZIONA, Israel, July 10, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress. PROLOR scientist Dr. Gili Hart will discuss data from preclinical studies of PROLOR's long-acting versions of Factor VIIa (Factor Vlla-CTP) and Factor lX (Factor IX-CTP) in two posters at the Congress.
Top-line results of these studies were previously reported by PROLOR. They showed that in hemophilic mouse models, PROLOR's long-acting Factor VIIa-CTP and Factor IX-CTP demonstrated superior performance on multiple measures of clotting efficacy compared to commercially available Factor VIIa and Factor IX, including survival following a bleeding challenge, generation of the pro-clotting enzyme thrombin, duration of clotting activity and number of spontaneous re-occurring bleeding episodes.
PROLOR CEO Dr. Abraham Havron commented, "The WFH World Congress is a comprehensive meeting that brings together leading researchers, physicians and patient representatives committed to improved therapies for hemophilia. We are pleased to have the opportunity to present the promising data from preclinical studies of our long-acting clotting factors to these opinion leaders as we advance them towards human clinical studies."
The posters,"F VIIa-CTP and F IX-CTP are novel long-acting coagulation factors with prolonged hemostatic activity in hemophilic animal models," Hart G, Monahan P, Seligsohn U, Zakar M, Hershkovitz O, Bar-Ilan A, Fima E, will be presented today at the WFH World Congress in Paris, France.
The biannual WFH World Congress is the largest global event focusing on bleeding disorders and features presentations, workshops and exhibits on cutting-edge trends in research and treatment for hemophilia and other inherited bleeding disorders. Participants include doctors, scientists, healthcare workers, people with bleeding disorders and hemophilia organizations. The Congress is being held from July 8- July 12, 2012. For more information, visit http://www.wfhcongress2012.org/
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins. PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial. It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development. For more information, visit www.prolor-biotech.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
SOURCE PROLOR Biotech, Inc.